Evaluation of cooperative anti-leukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia

• NSG mouse-engrafting CML LSC display CD26 and DPPIV activity• The DPPIV-targeting drug vildagliptin counteracts mobilization of CML LSC• Vildagliptin and sitagliptin did not modulate growth or survival of CML cells• Vildagliptin therapy did not prevent engraftment of CML LSC in NSG mice• Vildagliptin failed to promote TKI effects on CML engraftment in NSG mice

Source: Experimental Hematology - October 13, 2017 Category: Hematology Authors: Michael Willmann, Irina Sadovnik, Gregor Eisenwort, Martin Entner, Tina Bernthaler, Gabriele Stefanzl, Emir Hadzijusufovic, Daniela Berger, Harald Herrmann, Gregor Hoermann, Peter Valent, Thomas R ülicke Source Type: research